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Drugs that cause bone loss
or osteoporosis

Pathophysiology

Objectives
Prevention

Treatment

Drugs that cause osteoporosis
• Glucocorticoids - Prednisone, Methylprednisolone
• Hormone blockers - Aromatase inhibitors (letrozole,
anastrozole, exemestane), GnRh agonists, Anti-androgen
(5 alfa reductase inhibitors and androgen receptor
blockers), Progesterone only contraception.
• Anticonvulsants - enzyme inducers that breakdown
vitamin D (phenytoin, phenobarbital, carbamazepine,
primidone), Levetiracetam, Drugs that cause chronic
metabolic acidosis (Topiramate, Zonisamide)
• Antidiabetic Meds - Thiazolidinediones and SGLT-2
inhibitors
• Thyroid hormone excess.
• PPIs and SSRIs

Drugs that cause osteoporosis
• Diuretics - Furosemide, caffeine (urine calcium loss)
Acetazolamide (metabolic acidosis)
• Anticoagulants – Heparin, Warfarin
• Misc - Lithium increases PTH and bone turnover.
• Cyclosporine and Tacrolimus – cause increased bone turnover and
bone loss in animals and transplant patients.
• High dose methotrexate, such as used in oncology may increase
risk of OP - imbalance of bone resorption and formation.

• US Pharm. 2006;12:HS3-HS6.
• Ther Adv Muskuloskel Dis: 2014, Vol. 6(5) 185 - 202

• Steroid
Induced
Osteoporosis

Steroid induced osteoporosis - General
• Glucocorticoids are widely used and are effective in
treating many pulmonary, rheumatologic, autoimmune
gastrointestinal, dermatologic conditions and in organ
transplantation. Used in 0.5 - 1% of general population.
• Cause osteoporosis in a dose and time dependent
manner. The risk of bone loss is greatest within the first
6 to 12 months of long-term therapy and fractures can
occur in as early as 6 months.
• An estimated 30% to 50% of patients taking systemic
long-term steroids will eventually experience a fracture.

Steroid Osteoporosis - Incidence
• The annual incidence of vertebral and non-vertebral fracture from
the control arms of GIO-clinical trials was
– 5.1% per year chronic steroid use
– 2.5% per year in patients new to steroids
• In RA patients fracture incidence rate:
– >15 mg/day prednisone (16.0 per 1000 person-year)
– < 15 mg/day prednisone (5 to 9 per 1000 person-years).
– after discontinuation of steroids the fracture incidence
returned to baseline levels only after 12 months
• In older Caucasians with polymyalgia and giant cell arteritis
– incidence fracture rates approximately 14.5 per 1000 personyears, 65% higher than in control population.

Steroid Osteoporosis - Incidence
• In COPD patients increase risk of osteoporosis –
depending on use of oral steroids, smoking, BMI and
decreased mobility.
• A Cochrane systematic – 2-3 years of usual doses of
inhaled glucocorticoids showed no evidence of increased
risk of fracture or loss of BMD.
• Inhaled steroids > 8 years and > 600 μg/day of
beclomethasone or equivalent resulted in an increased
risk of fragility fractures

Steroid Induced Osteoporosis - Clinical
• Dexa BMD may underestimate risk of fractures.
Fracture risk increases even before bone density changes
• Frax helps to risk stratify but does not take into account dose and
duration. FRAX can be adjusted for daily dosage but not for the
cumulative dosage or length of use.
• High risk individuals are elderly men and women,
postmenopausal women, and individuals with other risk factors
including underlying disease.
• Other risk factors are age, low BMI, smoking, alcohol and IV
pulsed steroids.

Prevention and Treatment
• Use as little steroid as possible and use topical over
systemic. Optimize the use of steroid sparing agents and
DMARDs
• Calcium 1200 mg vitamin D3 2000 -5000 iu depending on
body weight.
• Weekly alendronate or risedronate or IV Zolendronic acid.
IM Denosumab, Rare SERMS and Calcitonin.
• Anabolic agents Teriparatide and Abaloparatide and the
newer agent Romozosumab in high risk patient with
osteoporotic fractures or very low T scores and elderly.

GIOP Guidelines – Initial Fx risk Assessment
• ACR 2017 - Baseline FRAX/ BMD (within 6 months of
GC initiation)
• IOF/ECTS 2012 - Clinical risk factor (i.e., FRAX without
BMD); if risk intermediate: BMD
• NOGG 2017 UK - UK FRAX model (GC-adjusted:
medium dose 2.5 -7.5 mg/d; high dose ≥ 7.5 mg/d)

• SIM/Italian - 2016 - DeFRA (FRAX derived Fx risk
assessment GC-adjusted)

GIOP Guidelines - Treatment
• ACR - First line: (in order of preference: oral BPS, IV BPS,
teriparatide, denosumab), (raloxifene for PM women none of
the medications listed above is appropriate).
Second
line: If Fx, ≥ 18 months of Rx or ≥ 10%/year loss of BMD:
teriparatide or denosumab or consider IV BPS if poor
absorption/poor adherence.
• IOF/ECTS - First line - all meds no Raloxifene
• NOGG UK - First line: oral BPS, Second line: IV BPS or
teriparatide
• Italian - Without OP Fx: First line: alendronate, risedronate,
zoledronic acid. Second line: denosumab
• With OP Fx: First line: teriparatide. Second line: denosumab,
zoledronic acid. Third line: alendronate, risedronate,
ibandronate, strontium ranelate

GIOP - Clinical trials – Alendronate
• In a 12-month randomized, placebo-controlled clinical trial, 477
patients in GIOP - daily ALN 5 and 10 mg
– Increased BMD 2.1 and 2.9% increase in L-spine BMD vs 0.4%
decline in placebo.
– FN BMD 1%, 1,2% and -1.2%. Bone loss in placebo pts
– Bone loss was duration dependent - 0.8% in 4mo, - 1.4% in 412 mo and 2.9% after 12 mo.
• In 208 patients in the open-label extension study at 2 yrs.
– Vert fractures 0.7% on ALN vs 6.8% in placebo.
• Observational data from a Swedish national database - ALN
significantly reduced the risk of hip fracture in 1802 GIOP on ALN
1802 matched GIOP controls (HR 0.35, 95% CI, 0.22–0.54)

GIOP - Clinical trials – Zolendronic Acid
• Of 833 GIOP IV Zoledronic acid 5 mg (416 pts)
V/S 5 mg oral Risedronate(417 pts)
• Higher BMD increase in IV Zol 4.06% compared
to 2.71% in the lumbar spine in treatment arm
2.6% vs 0.6% in the prevention arm at 12 mo.
• No difference in fracture rate - possibly due to a
low fracture rate in the population under
analysis in an active comparator study that did
not require a BMD inclusion criteria.

GIOP - Clinical trials – Teriparatide
• 18 month clinical trials 428 pts 214 each Teriparatide
ALN 10 mg daily TP was superior to ALN.
• Small number of vertebral fracture at 24 and 36 months
(0.6% vs 6.1% and 1.7% vs 7.7% respectively).
• No difference in non-vertebral fractures 5.6% vs 3.7%.
• Lumbar spine BMD increased 7.2% vs 3.4%
• Consider teriparatide in selected, high-risk patients (i.e.,
older adults starting higher dose steroids, multiple prior
fractures, and very low initial bone mass), potentially
even as an initial GIOP drug.

Teriparatide vs Alendronate in GIOP: 36 mo.
• BMD - 11.0% versus 5.3% for lumbar spine, 5.2% versus 2.7%
for total hip, and 6.3% versus 3.4% for femoral neck (P <
0.001 for all)
• Teriparatide increases from baseline in (PINP) and (OCN) (P <
0.01), and increases (CTX)
• ALN decreases in PINP, OC, and CTX
• Vertebral # TP vs ALN (3 [1.7%] of 173 versus 13 [7.7%] of
169; P = 0.007
• Non-Vert # (16 [7.5%] of 214 TP vs 15 [7.0%] of 214 ALN ; P =
0.843)

GIOP – Meta analysis – Vertebral Fx
• A 2016 meta-analysis on bisphosphonates for
GIOP included 27 randomized controlled trials
containing 3075 patients.
• In this analysis, 7.7% of people experienced a
new vertebral fracture in the control arm
compared with 4.4% in the bisphosphonate arm
• Overall fracture risk reduction was 43% with
bisphosphonates (95% CI, 9.0 to 65.0%).

• Aromatase inhibitors
Induced bone loss

Aromatase inhibitors
• Letrozole, Anastrozole, Exemestane.
• Enhances menopausal bone loss and increases risk of
fractures. 18-20% fracture incidence over 5 yrs. 2-3%
increase for each additional year of AI.
• Breast cancer patients had fracture incidence rate ratios of
1.25 (95% CI: 1.23–1.28) and 1.18 (95% CI: 1.14–1.22).
These ratios remained significantly increased for 10 yrs.
• Women taking aromatase inhibitors were at an increased
risk of fracture as compared with women taking tamoxifen
(HR 1.48; 95% CI: 0.98–2.22).

International Expert GP
• All women on AI therapy with ≥1 of the following
• T-score ≤ –2.0.
• Any 2 of the following risk factors
– T-score < –1.5
– age >65 yr,
– low BMI (<20 kg/m 2 ),
– family history of hip fracture,
– personal history of fragility fracture after age 50,
– oral corticosteroid use >6 mo
– smoking

Prevention and Treatment
• Zolendronic acid – IV 4 mg every 6 months 5 yrs
–
–
–
–

1065 pts L spine BMD LS 4.39% TH 1.9%
632 pts L spine BMD LS 6.19% TH 2.57 %
395 BMD /558 BMD LS 4.94% TH 1.22%
527 pts BMD LS 5.98% TH NA

• Risedronate – 35 mg weekly

– 150 BMD/260 pts BMD 1.1% and -0.7%
– 908/1410 pts BMD 1.1% and Hip -0.7%

• Meta Analysis:

– Early Breast Cancer Clinical Trials Gp (EBCTCG),
decreasing the incidence of bone recurrence by 34%
and breast cancer specific mortality by 17% .

Prevention and Treatment
• Denosumab – 60 mg every 6 months
– 252/252 pts BMD L Spine 6.2% and TH 2.7%
– 3420/3420 pts BMD L spine 10.2% and TH 7.92%
– Fracture risk OR 0.53 (CI 0.333–0.85, p=0.009)

• ONJ risk 1% per year.

• Androgen
Deprivation Therapy

Gnrh – Agonists Androgen Deprivation
• Luprolide, goserelin, triptorelin, historelin
• Used in treatment of Endometriosis,
premenopausal breast cancer, prostate cancer
• Decreases in BMD by 2 - 5% in the first year and
the risk of hip and vertebral fractures increases
to 20 - 50% at 5 years
• IV BPS, Denosumab, oral BPS
• Alternatives to ADT include antiandrogens, such
as bicalutamide, flutamide, and nilutamide, in
men without bone metastases.

• Progesterone only
contraception

Pathophysiology - Progestins
• Progestins - androgenic, antiandrogenic, glucocorticoids.
Mineralocorticoid effect. Variable effect on E2 levels.
• DMPA - suppresses ovarian production of estrogen and
deterioration of bone mass. MPA inhibits gonadotropin
secretion of LH and FSH. Decrease peak bone mass.
• MPA exhibits corticosteroid properties and can decrease
osteoblast differentiation by occupying the glucocorticoid
receptor. Stopping after 2 years may reverse bone effects.
• Androgenic progestins, including nortestosterone and
norethindrone, may have a positive effect on bone mass.

Bone Health - Estradiol levels

Effect of Progestins - bone

Oral Progestins – Bone Density
• 9 breastfeeding women using POPs vs 19 women using
barrier methods However, half of the control group
(n = 10) was formula feeding. Although all women showed
decline in BMD which was less in POP users.
• Implant - not associated with bone loss. Estradiol well
maintained.
• Threshold theory postulated by Barbeiri
• Group A: The use of progestin-only contraceptives leading
to an estradiol level between 30 and 50 pg/ml or higher
does not seem to lead to an accelerate bone loss.
• Group B: Serum estradiol levels between 20 and 30 pg/ml
as reported with the use of DMPA seem detrimental to
bone health and should therefore be avoided.

• Antiepileptic Drugs
and Osteoporosis

Anti Epileptic Drugs - Osteoporosis
• There is increased risk of fracture and decreased
BMD and bone loss with AEDs
• Increased fractures may be due to falls related to
the underlying disease(stroke, cerebral palsy),
seizures and AED use.
• Other risk factors include age, sex, smoking,
duration of AED treatments and type of AEDs
(enzyme inducers and non enzyme inducers) and
single or combination.

AED and fracture risk: meta-analysis
• Increase in fracture risk among users of AEDs involving
1,292,910 participants, with a mean/median age of 36 –
82 years (relative risk (RR) = 1.86; 95% confidence interval
(CI) 1.62–2.12).
• Both liver enzyme-inducing antiepileptic drugs (LEI AEDs)
and non-LEI AEDs were associated with an increase in
fracture risk, although the estimate for LEI AEDs was higher
than that of non-LEI AEDs (RR = 1.18; 95% CI 1.11–1.25).
• Use of phenobarbiturate (PB), topiramate (TPM) and
phenytoin (PHT) suggested an increase in fracture risk of
78%, 39% and 70%, respectively
•

Chunhong Shen, et al Bone. 2014 Jul;64:246-53.

Antiepileptic Treatment - with Bone Loss:
• AEDs, decrease BMD - 10 and 16 percent below controls.
• Men and women appear to be affected similarly
• A meta-analysis of 12 studies – AED use associated with significant
deficit of BMD in both hip and spine with mean Z-score deviations of 0.56 and -0.38, respectively.
• However, a cross-sectional study of premenopausal women found BMD
to be normal despite AED monotherapy for an average of 8 to 13 years
• In children, reduced BMD at axial and appendicular sites has been
described but not as consistently as in older adults.
• Age, AED duration, monotherapy or polytherapy, type of drug (enzymeinducer phenytoin, phenobarbital, carbamazepine) or non–enzyme
inducer (valproate, ethosuximide, lamotrigine, clonazepam).

Pathophysiology - AEDs
• Xenobiotics upregulate 25(OH)D3-24-hydroxylase (CYP24) in the
kidney through activation of PXR. This enzyme catalyzes the
conversion of 25(OH)D to its inactive metabolite (24,25dihydroxyvitamin) rather than to its active metabolite (1,25dihydroxyvitamin D).
• AEDs are associated with decreased fractional calcium absorption,
secondary hyperparathyroidism, and increased bone turnover.
• Phenytoin and carbamazepine inhibit osteoblasts. Only phenytoin
has been shown to inhibit osteocalcin secretion-a hormone that
regulates calcium in the bone.
• Topiramate and Zonisamide - chronic metabolic acidosis.
• Valproic acid – Fanconi’s syndrome - Osteomalacia
• Newer agents Levetiracetam appears to be safe

• Miscellaneous Drugs
Osteoporosis and
Fractures

Proton Pump Inhibitors
• Several large observational studies suggest that PPI use is
associated with a modest increase in osteoporotic fracture
risk hip 20-60% and spine 40-60%. Greater than 1 year
increases the odds ratio (OR) to around 1.44, and more
than 7 years of exposure, the OR increases to 4.55
• Mechanism not known - calcium malabsorption due to low
acid suggested. Risk decreases when PPIs are DCed
• PPI use and BMD have found no clear association
• Dose and duration dependent and other risk factors
especially smoking and BPS use.

Thiazolidenediones – Fractures
• Once used extensively for treatment of type 2 DM. Now
limited use in select patients with Type 2 DM
• A meta-analysis of 10 randomized trials and two large
observational studies indicate TZDs double fractures in
women with type 2 DM but not in men.
• Usually non vertebral extremities small bone fractures, upper
arm and pelvis. Risk is related to duration of use of TZDs
• A meta-analysis of three population-based European cohort
studies also found a 1.2-1.5 fold increase in fractures in
women but not men on TZDs. But a UK study showed higher
risk in men and women and even young women.

Thiazolidinediones – Mechanism of OP
• Peroxisome proliferator-activated receptor γ (PPARγ)
expressed in stromal cells of the bone marrow,
osteoblasts, and osteoclasts, and plays an important role
in the differentiation of stromal precursor cells into OB.
• TZDs impair the differentiation of osteoblast precursors,
thereby preventing bone formation.
• TZDs may act on bone remodeling by increasing adiposity
of bone marrow, decreasing aromatase activity, and
promoting OC differentiation, leading to increased bone
resorption.

SGLT-2 inhibitors - Fractures and bone loss
• In diabetic patients with moderate renal impairment,
9.4% of patients treated with dapagliflozin (10 mg/d)
experienced bone fractures. No fractures were
observed in placebo-treated patients.
• Canagliflozin (300 mg/d) accelerated loss of total hip
BMD compared to placebo (−2.1% vs. −0.9%) during a
104 week trial in diabetic patients 55- 80 years of age.
• In the Canagliflozin Cardiovascular Assessment Study,
canagliflozin was associated with an increased
incidence of fractures: 4.0% of canagliflozin-treated
vs. 2.6% of placebo-treated patients.

SGLT-2 inhibitors – Mechanism of bone loss
• SGLT2 inhibitors promote weight loss, and the magnitude of
weight loss was correlated with a biomarker for bone resorption
(collagen type 1 β-carboxy-telopeptide). Weight loss explained
only a small percentage (~3%) of the variance of bone resorption
biomarkers.
• SGLT2 inhibitors can induce postural hypotension, which may
increase the risk of falls and fractures.
• Finally, women receiving canagliflozin (300 mg) experienced a
9.2% decrease in estradiol levels
• Increase in Serum P 0.61 mg/dl due to decreased GFR and
increased proximal tubular phosphate reabsorption. This
triggered increase in FGF 23 by 20% and decrease in 125D by
10% higher PTH 25% lower Uca.

SSRI – increased risk of fractures
• Several studies - SSRIs are associated with bone loss and
increased fracture risk. Fracture risk was highest at the hip
and nonvertebral sites vs spine. Older men and women.
Dose and duration related. Other risk factors smoking.
• Meta analysis: OR for fracture among SSRI - users to be
1.69 (95% CI 1.51–1.90; r2 = 89.9%) OR of 1.73(95% CI
1.51–1.9; p < 0.001).
• No decline in BMD. Serotonin receptors found on
osteoblasts and osteoclasts regulate bone homeostasis via
endocrine, autocrine, paracrine, and neuronal serotonin
pathways.

Anticoagulants - Heparin
• Unfractionated heparin (UFH) is associated with
drug-induced osteoporosis with long-term, highdose therapy.
• Bone loss occurs after six months of heparin therapy
with daily doses greater than 15,000 units.3
• Newer low-molecular-weight heparins (LMWHs),
Enoxaparin use resulted in no significant changes in
BMD in women treated throughout pregnancy and
six weeks after giving birth.3

Pathophysiology - Anticoagulants
• Heparin causes increased bone resorption by
stimulating osteoclasts and suppressing osteoblast
function, leading to decreased bone mass.
• Other proposed mechanisms include depletion of
mast cells in bone marrow and enhancement of
parathyroid hormone (PTH)
• It is controversial whether warfarin and loss of
vitamin K causes impaired bone formation.3

